शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
SAKARNSESakar Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 5 Feb, 2026 · 10:47 IST

Sakar Healthcare Q3 FY26 results: Revenue up 62%, PAT jumps 126% YoY

Revenue Growth 20pctPat Growth 25pctResults View source PDFExplain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+6.0%Reaction day
₹410.00
prior close
₹430.05
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+7.0% vs market
Pharmaceuticals peers, median of 157sector-0.5%+6.5% vs sector

On the reaction day the stock moved 7.0 pts more than Nifty Microcap 250 and 6.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
+1.2
15m
+0.6
30m
+0.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+6.0-1.0+7.0-0.5+6.5
Next day
+7.3-1.8+9.1-1.2+8.5
2d
+19.0+0.8+18.3+0.5+18.5
3d
+12.2+1.8+10.4+1.0+11.2
4d
+13.0+1.2+11.7+0.9+12.1
5d
+14.6+0.7+13.9+0.0+14.6
1w
+12.2-1.5+13.7-1.5+13.7
15d
+25.6-2.5+28.1-2.9+28.5
1m
+28.4-7.2+35.6-5.1+33.5
2m
+26.8-8.9+35.7-7.4+34.2
3m
+53.4+5.5+48.0+0.2+53.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare reported Q3 FY26 standalone revenue of Rs 70.34 crore, up 62% YoY from Rs 43.42 crore. Profit after tax surged 126% YoY to Rs 10.25 crore from Rs 4.53 crore. For 9M FY26, revenue grew 42% to Rs 180.64 crore and PAT rose 66% to Rs 19.46 crore. EPS stood at Rs 4.59 vs Rs 2.08. Results are unaudited and reviewed by statutory auditor J.S. Shah & Co.

Likely market impact

Strong top-line and bottom-line growth with margin improvement; positive for shareholders. Monitor sustainability of growth momentum.